Compare Stocks: BPMX, BNTC, EDIT, and PRTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$12.19	$12.64	$9.85 ▼ $16.76	$418.73M	0.27	122,980 shs	88,587 shs
BPMX Biopharmx		$0.00	$0.25 ▼ $6.30	$111.86M	N/A	2.15 million shs	336,508 shs
EDIT Editas Medicine	$2.70	$2.98	$1.66 ▼ $4.54	$414.67M	2.09	2.68 million shs	2.46 million shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	0.00%	-3.86%	-2.95%	+7.59%	-11.99%
BPMX Biopharmx	0.00%	0.00%	0.00%	0.00%	0.00%
EDIT Editas Medicine	0.00%	-16.41%	-4.26%	+9.76%	+0.37%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	+10.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$12.19	$12.64	$9.85 ▼ $16.76	$418.73M	0.27	122,980 shs	88,587 shs
BPMX Biopharmx		$0.00	$0.25 ▼ $6.30	$111.86M	N/A	2.15 million shs	336,508 shs
EDIT Editas Medicine	$2.70	$2.98	$1.66 ▼ $4.54	$414.67M	2.09	2.68 million shs	2.46 million shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	0.00%	-3.86%	-2.95%	+7.59%	-11.99%
BPMX Biopharmx	0.00%	0.00%	0.00%	0.00%	0.00%
EDIT Editas Medicine	0.00%	-16.41%	-4.26%	+9.76%	+0.37%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	+10.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	2.60	Moderate Buy	$24.80	103.45% Upside
BPMX Biopharmx	0.00	N/A	N/A	N/A
EDIT Editas Medicine	2.60	Moderate Buy	$6.00	122.22% Upside
PRTC PureTech Health	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BPMX, BNTC, EDIT, and PRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	EDIT Editas Medicine	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
8/11/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/17/2026	BNTC Benitec Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$3.71 per share	N/A
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	$40.52M	10.23	N/A	N/A	$0.28 per share	9.64
PRTC PureTech Health	$4.66M	91.01	N/A	N/A	$12.65 per share	1.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$37.92M	-$1.14	N/A	N/A	N/A	N/A	-34.82%	-34.11%	9/28/2026 (Estimated)
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
PRTC PureTech Health	-$109.74M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BPMX, BNTC, EDIT, and PRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
9/28/2026	Q4 2026	BNTC Benitec Biopharma	-$0.2671	N/A	N/A	N/A	N/A	N/A
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	N/A	56.82	56.82
BPMX Biopharmx	N/A	N/A	N/A
EDIT Editas Medicine	N/A	3.19	3.19
PRTC PureTech Health	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
BPMX Biopharmx	N/A
EDIT Editas Medicine	71.90%
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	4.80%
BPMX Biopharmx	N/A
EDIT Editas Medicine	3.10%
PRTC PureTech Health	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	34.35 million	32.71 million	No Data
BPMX Biopharmx	17	18.28 million	N/A	Not Optionable
EDIT Editas Medicine	230	153.58 million	148.82 million	Optionable
PRTC PureTech Health	100	24.34 million	23.05 million	Not Optionable

BPMX, BNTC, EDIT, and PRTC Headlines

Recent News About These Companies

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis ...

July 13, 2026 | finance.yahoo.com

PureTech Subsidiary Celea Begins Phase 3 IPF Study Comparing Deupirfenidone With Standard Therapy (PRTC)

July 13, 2026 | uk.finance.yahoo.com

PureTech entity Celea raises $180 million to move lung disease drug into late stage trial

July 2, 2026 | reuters.com

PureTech Health plc American Depositary Shares (PRTC) Real-Time

July 1, 2026 | nasdaq.com

2 UK shares tipped to more than double my money in 2026!

June 20, 2026 | uk.finance.yahoo.com

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

June 9, 2026 | finance.yahoo.com

PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

May 13, 2026 | businesswire.com

PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO

May 1, 2026 | proactiveinvestors.co.uk

PureTech Announces Annual Results for Year Ended December 31, 2025

April 29, 2026 | businesswire.com

PureTech Health: Notice of Results

April 13, 2026 | businesswire.com

PureTech Gains on Results

April 2, 2026 | baystreet.ca

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

April 2, 2026 | businesswire.com

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

March 25, 2026 | businesswire.com

PureTech to Present at the Leerink Partners Global Healthcare Conference

February 25, 2026 | businesswire.com

PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

February 19, 2026 | businesswire.com

PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

January 14, 2026 | seekingalpha.com

PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026 | finance.yahoo.com

PureTech CEO to present at JP Morgan Healthcare Conference

January 6, 2026 | msn.com

PureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the company

January 3, 2026 | finance.yahoo.com

PureTech Appoints Robert Lyne as Chief Executive Officer

December 18, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BPMX, BNTC, EDIT, and PRTC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$12.19 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.20 +0.01 (+0.08%)

As of 09/11/2026 04:10 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Biopharmx NYSEAMERICAN:BPMX

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.

Editas Medicine NASDAQ:EDIT

$2.70 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.65 -0.05 (-1.85%)

As of 05:03 AM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)

As of 09/11/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPMX, BNTC, EDIT, and PRTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPMX, BNTC, EDIT, and PRTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPMX, BNTC, EDIT, and PRTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BPMX, BNTC, EDIT, and PRTC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Biopharmx NYSEAMERICAN:BPMX

Editas Medicine NASDAQ:EDIT

PureTech Health NASDAQ:PRTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPMX, BNTC, EDIT, and PRTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPMX, BNTC, EDIT, and PRTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPMX, BNTC, EDIT, and PRTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BPMX, BNTC, EDIT, and PRTC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Biopharmx NYSEAMERICAN:BPMX

Editas Medicine NASDAQ:EDIT

PureTech Health NASDAQ:PRTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools